Agilent (A) 10-Q5 Mar 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Jan. 31, 2014
Document and Entity Information [Abstract]	'
Entity Registrant Name	'AGILENT TECHNOLOGIES INC.
Entity Central Index Key	'0001090872
Current Fiscal Year End Date	'--10-31
Entity Well-known Seasoned Issuer	'Yes
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	333,420,524
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	31-Jan-14

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Net revenue [Abstract]	'	'
Products	$1,366	$1,380
Services and other	313	300
Total net revenue	1,679	1,680
Costs and expenses:	'	'
Cost of products	626	637
Cost of services and other	170	163
Total costs	796	800
Research and development	177	179
Selling, general and administrative	488	484
Total costs and expenses	1,461	1,463
Income from operations	218	217
Interest income	2	2
Interest expense	-29	-25
Other income (expense), net	0	1
Income before taxes	191	195
Provision (benefit) for income taxes	-4	16
Net income	$195	$179
Net income per share:	'	'
Basic (in dollars per share)	$0.59	$0.52
Diluted (in dollars per share)	$0.58	$0.51
Weighted average shares used in computing net income per share:	'	'
Basic (in shares)	333	347
Diluted (in shares)	338	352
Cash dividends declared per common share	$0.13	$0.22

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'
Net Income	$195	$179
Other comprehensive income (loss):	'	'
Unrealized gain (loss) on investments, net of tax (expense) benefit of $1 and $(2)	-3	3
Unrealized gain (loss) on derivative instruments, net of tax (expense) benefit of $1 and $(2)	-2	6
Amounts reclassified into earnings related to derivative instruments, net of tax (expense) of $(1) and zero	0	-1
Foreign currency translation, net of tax benefit of $5 and zero	-55	56
Net defined benefit pension cost and post retirement plan costs:	'	'
Amortization of actuarial net loss, net of tax (expense) of $(4) and $(4)	13	14
Amortization of net prior service benefit, net of tax benefit of $4 and $4	-8	-8
Other comprehensive income (loss)	-55	70
Total comprehensive income	$140	$249

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Other comprehensive income (loss), tax, parenthetical disclosures [Abstract]	'	'
Unrealized gain (loss) on investments,tax	$1	($2)
Unrealized gain (loss) on derivative instruments, Tax	1	-2
Reclassification of (gains) and losses into earnings related to derivative instruments, tax	-1	0
Foreign currency translation, tax	5	0
Net defined benefit pension cost and post retirement plan costs, tax [Abstract]	'	'
Amortization of net loss, tax	-4	-4
Amortization of net prior service benefit, tax	$4	$4

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$2,742	$2,675
Accounts receivable, net	849	899
Inventory	1,088	1,066
Other current assets	394	343
Total current assets	5,073	4,983
Property, plant and equipment, net	1,129	1,134
Goodwill	3,017	3,047
Other intangible assets, net	859	916
Long-term investments	129	139
Other assets	431	467
Total assets	10,638	10,686
Current liabilities:	'	'
Accounts payable	430	432
Employee compensation and benefits	335	401
Deferred revenue	459	439
Other accrued liabilities	325	330
Total current liabilities	1,549	1,602
Long-term debt	2,695	2,699
Retirement and post-retirement benefits	274	294
Other long-term liabilities	673	802
Total liabilities	5,191	5,397
Commitments and Contingencies (Note 12)	'	'
Stockholders' equity:	'	'
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 605 million shares at January 31, 2014 and 602 million shares at October 31, 2013, issued	6	6
Treasury stock at cost; 271 million shares at January 31, 2014 and 269 million shares at October 31, 2013	-9,707	-9,607
Additional paid-in-capital	8,820	8,723
Retained earnings	6,289	6,073
Accumulated other comprehensive income	36	91
Total stockholder's equity	5,444	5,286
Non-controlling interest	3	3
Total equity	5,447	5,289
Total liabilities and equity	$10,638	$10,686

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) (USD $)	Jan. 31, 2014	Oct. 31, 2013
Stockholders' Equity Attributable to Parent [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	125,000,000	125,000,000
Preferred stock, issued and outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued and outstanding (in shares)	605,000,000	602,000,000
Treasury stock at cost, shares (in shares)	271,000,000	269,000,000

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Net Income	$195	$179
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	96	94
Share-based compensation	36	31
Excess tax benefit from share-based plans	-3	-2
Deferred taxes	-5	-2
Excess and obsolete inventory and inventory-related charges	11	10
Other non-cash expenses, net	6	2
Changes in assets and liabilities:	'	'
Accounts receivable	40	53
Inventory	-33	-34
Accounts payable	-1	-7
Employee compensation and benefits	-62	-70
Other assets and liabilities	-86	-9
Net cash provided by operating activities	194	245
Cash flows from investing activities:	'	'
Investments in property, plant and equipment	-45	-59
Proceeds from sale of property, plant, and equipment	0	1
Purchase of other investments	0	-15
Proceeds from sale of investments	0	11
Acquisitions of businesses and intangible assets, net of cash acquired	-2	-10
Net cash used in investing activities	-47	-72
Cash flows from financing activities:	'	'
Issuance of common stock under employee stock plans	73	52
Payment of dividends	-44	-35
Purchase of non-controlling interest	0	-3
Excess tax benefit from share-based plans	3	2
Treasury stock repurchases	-100	-79
Net cash used in financing activities	-68	-63
Effect of exchange rate movements	-12	-11
Net Increase in cash and cash equivalents	67	99
Cash and cash equivalents at beginning of period	2,675	2,351
Cash and cash equivalents at end of period	$2,742	$2,450

OVERVIEW_BASIS_OF_PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jan. 31, 2014
Accounting Policies [Abstract]	'
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'

	1	OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a measurement company, providing core bio-analytical and electronic measurement solutions to the life sciences, diagnostics and genomics, chemical analysis, communications and electronics industries.

	Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, all dates refer to our fiscal year and fiscal quarters.

	Agilent Separation. On September 19, 2013, Agilent announced plans to separate into two publicly traded companies, one comprising of the life sciences, diagnostics and chemical analysis businesses that will retain the Agilent name, and the other that will be comprised of the electronic measurement business that will be renamed Keysight Technologies, Inc. (“Keysight”). As part of the separation, Agilent plans to transfer the assets, liabilities and operations of the electronic measurement business to Keysight prior to the distribution. The separation is expected to occur through a tax-free pro rata distribution of Keysight shares to Agilent shareholders and is expected to be completed early in November 2014. Keysight was incorporated in Delaware as a wholly-owned subsidiary of Agilent on December 6, 2013.

	Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2014 and 2013 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K.

	In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary to present fairly our condensed consolidated balance sheet as of January 31, 2014 and October 31, 2013, condensed consolidated statement of comprehensive income for the three months ended January 31, 2014 and 2013, condensed consolidated statement of operations for the three months ended January 31, 2014 and 2013, and condensed consolidated statement of cash flows for the three months ended January 31, 2014 and 2013.

	The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-retirement plan assumptions, restructuring and accounting for income taxes.

	Update to Significant Accounting Policies. There have been no material changes to our significant accounting policies, as compared to the significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2013.

	In the first quarter of 2014, we adopted the authoritative guidance for reporting of amounts reclassified out of accumulated other comprehensive income. For additional details related to the updated authoritative guidance, see Note 2, "New Accounting Pronouncements".

	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $105 million and $112 million as of January 31, 2014 and October 31, 2013, respectively. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 8, "Fair Value Measurements" for additional information on the fair value of financial instruments.

	Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

	The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

	If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In October 2013, we combined the life sciences and diagnostics and genomics segments to form the life sciences and diagnostics segment. As a result, Agilent has three segments, life sciences and diagnostics, chemical analysis, and electronic measurement segments.

	In fiscal year 2013, we assessed goodwill impairment for our four reporting units which consisted of two segments: chemical analysis and electronic measurement; and two reporting units under the life sciences and diagnostics segment. The first of these two reporting units related to our life sciences business and the second related to our diagnostics business. We performed a qualitative test for goodwill impairment of the following three reporting units, as of September 30, 2013: the chemical analysis segment, the electronic measurement segment, and the reporting unit relating to life sciences. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these reporting units are greater than their respective carrying values. We performed a quantitative test for goodwill impairment of the reporting unit related to our diagnostics business as of September 30, 2013. Based on the results of our quantitative testing, the fair value was significantly in excess of the carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the three months ended January 31, 2014 and 2013.

	Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

	In July 2012, the FASB simplified the guidance for testing for impairment of indefinite-lived intangible assets other than goodwill. The changes are intended to reduce compliance costs. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The revised guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allowed the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2013. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible asset is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. There was no impairment of indefinite-lived intangible asset during the three months ended January 31, 2014 and 2013.

NEW_ACCOUNTING_PRONOUNCEMENTS

NEW ACCOUNTING PRONOUNCEMENTS	3 Months Ended
NEW ACCOUNTING PRONOUNCEMENTS	Jan. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
NEW ACCOUNTING PRONOUNCEMENTS	'
	2. NEW ACCOUNTING PRONOUNCEMENTS

	In December 2011, the FASB issued guidance related to the enhanced disclosures that will enable the users of financial statements to evaluate the effect or potential effect of netting arrangements of an entity's financial position. The amendments require improved information about financial instruments and derivative instruments that are either offset or subject to enforceable master netting arrangements or similar agreement. The guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. We adopted this guidance in the first quarter of 2014. There was no impact to our consolidated financial statements due to the adoption of this guidance.

	In February 2013, the FASB issued the guidance for reporting of amounts reclassified out of accumulated other comprehensive income. The revised guidance requires reporting the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures that provide additional detail about these amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those years. We adopted this guidance in the first quarter of 2014 and have presented the requisite disclosures in the condensed consolidated statement of comprehensive income and in the notes to the financial statements.

	In March 2013, the FASB issued an amendment to the accounting guidance on foreign currency matters in order to clarify the guidance for the release of cumulative translation adjustment. The guidance requires that a parent deconsolidate a subsidiary or derecognize a group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) if the parent ceases to have a controlling financial interest in that group of assets. The guidance is effective for interim and annual periods beginning on or after December 15, 2013. We do not expect a material impact to our consolidated financial statements due to the adoption of this guidance.

	In July 2013, the FASB issued an amendment to the accounting guidance related to the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. The guidance requires an unrecognized tax benefit to be presented as a decrease in a deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward exists and certain criteria are met. This guidance is effective prospectively for annual and interim reporting periods beginning after December 15, 2013 and is consistent with our current practice.

	Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Jan. 31, 2014
Share-based Compensation [Abstract]	'
SHARE-BASED COMPENSATION	'
	3. SHARE-BASED COMPENSATION

	Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values.

	The impact on our results for share-based compensation was as follows:



		Three Months Ended

		January 31,

		2014			2013

		(in millions)
	Cost of products and services	$	8		$	8

	Research and development	6			4

	Selling, general and administrative	23			19

	Total share-based compensation expense	$	37		$	31


	At January 31, 2014, share-based compensation capitalized within inventory was $2 million. For the three months ended January 31, 2014 and 2013, the windfall tax benefit realized from exercised stock options and similar awards was $3 million and $2 million, respectively.

	The following assumptions were used to estimate the fair value of the options and LTPP grants.



		Three Months Ended
		January 31,
		2014		2013
	Stock Option Plans:

	Weighted average risk-free interest rate	1.7	%	0.9	%
	Dividend yield	1	%	1	%
	Weighted average volatility	39	%	39	%
	Expected life	5.8 yrs		5.8 yrs

	LTPP:
	Volatility of Agilent shares	36	%	37	%
	Volatility of selected peer-company shares	13%-57%		6%-64%

	Price-wise correlation with selected peers	47	%	49	%

	The fair value of share-based awards for employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP were valued using a Monte Carlo simulation model. Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective and complex assumptions, including the option’s expected life and the price volatility of the underlying stock. The estimated fair value of restricted stock unit awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the purchase price and uses the purchase date to establish the fair market value.

	We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior.

INCOME_TAXES

INCOME TAXES	3 Months Ended
INCOME TAXES	Jan. 31, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	4. INCOME TAXES

	The company’s effective tax rate was (2.0) percent and 8.2 percent for the three months ended January 31, 2014 and 2013, respectively. The income tax benefit was $4 million for the three months ended January 31, 2014. The income tax expense was $16 million for the three months ended January 31, 2013.

	The income tax provision for the three months ended January 31, 2014 included a net discrete benefit of $35 million primarily due to the settlement of an Internal Revenue Service ("IRS") audit in the U.S. and the recognition of tax expense related to the repatriation of dividends to the U.S. The income tax provision for the three months ended January 31, 2013 included a net discrete tax benefit of $11 million primarily due to the recognition of research and development tax credits relating to the company's prior fiscal year.

	In connection with the settlement of the 2006-2007 IRS audit we identified an overstatement of approximately $65 million in our long-term tax liabilities. The overstatement was recorded in 2008 as a cumulative effect of a change in accounting principle when we adopted Accounting Standard Codification 740-10, Income Taxes. Accordingly, we corrected the error in the current period by reducing long-term tax liabilities and increasing retained earnings by $65 million. The correction has no impact on net income or cash flows in any prior period or the current quarter, and is not considered material to total liabilities or equity in any prior period or for the current quarter.

	In the U.S., tax years remain open back to the year 2008 for federal income tax purposes and the year 2000 for significant states. On January 29, 2014 we reached an agreement with the IRS for the tax years 2006 through 2007. The settlement resulted in the recognition of previously unrecognized tax benefits of $160 million, offset by a tax liability on foreign distributions of approximately $125 million principally related to additional foreign earnings that was recognized in conjunction with the settlement. Agilent's U.S. federal income tax returns for 2008 through 2010 are currently under audit by the IRS. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2003. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	3 Months Ended
	Jan. 31, 2014
Earnings Per Share [Abstract]	'
NET INCOME PER SHARE	'
	5. NET INCOME PER SHARE

	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:



		Three Months Ended
		January 31,
		2014		2013
		(in millions)
	Numerator:

	Net income	$	195	$	179

	Denominator:
	Basic weighted-average shares	333		347

	Potentially dilutive common shares equivalents — stock options and other employee stock plans	5		5

	Diluted weighted-average shares	338		352


	The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense, the tax benefits or shortfalls recorded to additional paid-in capital and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense and tax benefits or shortfalls collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

	We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. For the three months ended January 31, 2014, no options to purchase shares were excluded from the calculation of diluted earnings per share as compared to 5,600 shares for the three months ended January 31, 2013. In addition, we also exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price, unamortized fair value and excess tax benefits or shortfalls collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive. For the three months ended January 31, 2014 we excluded no additional shares as compared to 20,000 additional shares excluded for the three months ended January 31, 2013.

INVENTORY

INVENTORY	3 Months Ended
	Jan. 31, 2014
Inventory, Net [Abstract]	'
INVENTORY	'
	6. INVENTORY



		January 31,		October 31,
		2014		2013
		(in millions)
	Finished goods	$	557	$	552

	Purchased parts and fabricated assemblies	531		514

	Inventory	$	1,088	$	1,066

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Jan. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	7. GOODWILL AND OTHER INTANGIBLE ASSETS

	The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2014:



		Life Sciences and Diagnostics			Chemical Analysis			Electronic			Total
								Measurement
		(in millions)
	Goodwill as of October 31, 2013	$	1,883		$	745		$	419		$	3,047

	Foreign currency translation impact	(13		)	(8		)	(9		)	(30		)
	Goodwill arising from acquisitions/adjustments	—			—			—			—

	Goodwill as of January 31, 2014	$	1,870		$	737		$	410		$	3,017


	The components of other intangibles as of January 31, 2014 and October 31, 2013 are shown in the table below:



		Purchased Other Intangible Assets
		Gross			Accumulated			Net Book
		Carrying			Amortization			Value
		Amount			and
					Impairments
		(in millions)
	As of October 31, 2013:

	Purchased technology	$	1,019		$	460		$	559

	Backlog	14			14			—

	Trademark/Tradename	176			40			136

	Customer relationships	401			215			186

	Total amortizable intangible assets	1,610			729			881

	In-Process R&D	35			—			35

	Total	$	1,645		$	729		$	916

	As of January 31, 2014:

	Purchased technology	1,020			493			527

	Backlog	14			14			—

	Trademark/Tradename	176			44			132

	Customer relationships	398			229			169

	Total amortizable intangible assets	1,608			780			828

	In-Process R&D	31			—			31

	Total	$	1,639		$	780		$	859


	During the three months ended January 31, 2014, there were no additions to goodwill. During the three months ended January 31, 2013, we recorded additions to goodwill of $10 million primarily related to the acquisition of two businesses. During the three months ended January 31, 2014, there were no additions to other intangible assets. During three months ended January 31, 2013, we recorded additions to other intangible assets of $1 million. During the three months ended January 31, 2014, intangible assets decreased by $7 million due to the impact of foreign exchange translation. During the three months ended January 31, 2013, intangible assets increased by $33 million due to the impact of foreign exchange translation. During the three months ended January 31, 2014 and 2013, we transferred $4 million and $22 million, respectively, from in-process R&D to purchased technology as projects were completed.

	Amortization of intangible assets was $51 million and $51 million for the three months ended January 31, 2014 and 2013, respectively. Future amortization expense related to existing finite-lived purchased intangible assets is estimated to be $143 million for the remainder of 2014, $181 million for 2015, $154 million for 2016, $106 million for 2017, $70 million for 2018, $55 million for 2019, and $119 million thereafter.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Jan. 31, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	8. FAIR VALUE MEASUREMENTS

	The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

	Fair Value Hierarchy

	The guidance establishes a fair value hierarchy that prioritizes inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

	Level 1- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

	Level 2- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

	Level 3- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis

	Assets and liabilities measured at fair value on a recurring basis as of January 31, 2014 were as follows:



					Fair Value Measurement at January 31, 2014 Using
		January 31,			Quoted Prices			Significant			Significant
		2014			in Active			Other			Unobservable
					Markets for			Observable			Inputs
					Identical Assets			Inputs			(Level 3)
					(Level 1)			(Level 2)
		(in millions)
	Assets:

	Short-term

	Cash equivalents (money market funds)	$	2,080		$	2,080		$	—		$	—

	Derivative instruments (foreign exchange contracts)	8			—			8			—

	Long-term
	Trading securities	46			46			—			—

	Available-for-sale investments	22			22			—			—

	Total assets measured at fair value	$	2,156		$	2,148		$	8		$	—

	Liabilities:

	Short-term
	Derivative instruments (foreign exchange contracts)	$	16		$	—		$	16		$	—

	Long-term
	Deferred compensation liability	46			—			46			—

	Total liabilities measured at fair value	$	62		$	—		$	62		$	—



	Assets and liabilities measured at fair value on a recurring basis as of October 31, 2013 were as follows:



					Fair Value Measurement at October 31, 2013 Using
		October 31,			Quoted Prices			Significant			Significant
		2013			in Active			Other			Unobservable
					Markets for			Observable			Inputs
					Identical Assets			Inputs			(Level 3)
			(Level 1)		(Level 2)
		(in millions)
Assets:

Short-term

Cash equivalents (money market funds)	$	1,968		$	1,968		$	—		$	—

Derivative instruments (foreign exchange contracts)	7			—			7			—

Long-term
Trading securities	51			51			—			—

Available-for-sale investments	25			25			—			—

Total assets measured at fair value	$	2,051		$	2,044		$	7		$	—

Liabilities:

Short-term
Derivative instruments (foreign exchange contracts)	$	6		$	—		$	6		$	—

Long-term
Deferred compensation liability	51			—			51			—

Total liabilities measured at fair value	$	57		$	—		$	57		$	—


Our money market funds, trading securities investments and available-for-sale investments are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable.

Trading securities and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Investments designated as available-for-sale and certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in other comprehensive income. Realized gains and losses from the sale of these instruments are recorded in net income.

Impairment of Investments. There were no impairments for investments for the three months ended January 31, 2014 and 2013.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-Lived Assets

For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income during the three months ended January 31, 2014 and 2013:



	Three Months Ended
	January 31,
	2014			2013
	(in millions)
Long-lived assets held and used	$	—		$	—

Long-lived assets held for sale	$	—		$	1


For the three months ended January 31, 2014 and 2013, there were no impairments of long-lived assets held and used. For the three months ended January 31, 2014, there were no impairments of long-lived assets held for sale. For the three months ended January 31, 2013, long-lived assets held for sale with a carrying value of $3 million were written down to their fair value of $2 million. Fair value for the impaired long-lived assets was measured using level 2 inputs and impairments were included in net income for the period stated.

DERIVATIVES

DERIVATIVES	3 Months Ended
	Jan. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
DERIVATIVES	'
	9. DERIVATIVES

	We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of risk management strategy, we use derivative instruments, primarily forward contracts, purchased options, and interest rate swaps, as needed, to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates and interest rates.

	Fair Value Hedges

	We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short term investments. As of January 31, 2014, all interest rate swap contracts had either been terminated or had expired.

	On November 25, 2008, we terminated two interest rate swap contracts associated with our 2017 senior notes that represented the notional amount of $400 million. The gain to be amortized at January 31, 2014 was $20 million. On June 6, 2011, we also terminated five interest rate swap contracts associated with our 2015 senior notes that represented the notional amount of $500 million. The gain to be amortized at January 31, 2014 was $11 million. On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million. The gain to be amortized at January 31, 2014 was $25 million. All deferred gains from terminated interest rate swaps are being amortized over the remaining life of the respective senior notes.

	Cash Flow Hedges

	We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income. Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) over the life of the option contract. Ineffectiveness in the three months ended January 31, 2014 and 2013 was not significant. For the three months ended January 31, 2014 and 2013 gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant.

	In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income of $3 million to be amortized to interest expense over the life of the 2022 senior notes.

	Other Hedges

	Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

	Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

	A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

	The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of January 31, 2014, was $11 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of January 31, 2014.

	There were 135 foreign exchange forward contracts and 16 foreign exchange option contracts open as of January 31, 2014 and designated as cash flow hedges. There were 181 foreign exchange forward contracts open as of January 31, 2014 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of January 31, 2014 were as follows:



			Derivatives in Cash Flow								Derivatives
			Hedging Relationships								Not
											Designated
											as Hedging
											Instruments
			Forward				Option				Forward
			Contracts				Contracts				Contracts
	Currency		Buy/(Sell)				Buy/(Sell)				Buy/(Sell)
			(in millions)
	Euro		$	(30	)		$	—			$	167

	British Pound		(14		)		—				2

	Canadian Dollar		(35		)		—				—

	Australian Dollars		12				—				6

	Malaysian Ringgit		108				—				10

	Japanese Yen		(62		)		(83		)		(19		)
	Other		(15		)		—				(21		)

	Totals		$	(36	)		$	(83	)		$	145


	The notional amounts within derivatives not designated as hedging instruments include forward cross currency contracts of Danish Krone equivalent of $70 million to sell Euro, and of Danish Krone equivalent of $5 million to sell Japanese Yen.

	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of January 31, 2014 and October 31, 2013 were as follows:



	Fair Values of Derivative Instruments
	Asset Derivatives										Liability Derivatives
		Fair Value										Fair Value
Balance Sheet Location		January 31,				October 31,				Balance Sheet Location		January 31,		October 31,
		2014				2013						2014		2013
(in millions)
Derivatives designated as hedging instruments:

Cash flow hedges
Foreign exchange contracts
Other current assets		$	5			$	4			Other accrued liabilities		$	7	$	4

Derivatives not designated as hedging instruments:

Foreign exchange contracts

Other current assets		$	3			$	3			Other accrued liabilities		$	9	$	2

Total derivatives		$	8			$	7					$	16	$	6


The effect of derivative instruments for interest rate swap contracts and foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:




	Three Months Ended
	January 31,
	2014				2013
	(in millions)
Derivatives designated as hedging instruments:

Cash Flow Hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income	$	(3	)		$	8

Gain (loss) reclassified from accumulated other comprehensive income into cost of sales	$	(1	)		$	1

Derivatives not designated as hedging instruments:
Gain (loss) recognized in other income (expense)	$	(1	)		$	3


The estimated amount of existing net loss at January 31, 2014 that is expected to be reclassified from other comprehensive income to cost of sales within the next twelve months is $3 million.

RESTRUCTURING

RESTRUCTURING	3 Months Ended
	Jan. 31, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	10. RESTRUCTURING

	In the second quarter of 2013, in response to slow revenue growth due to macroeconomic conditions, we accrued for a targeted restructuring program to reduce Agilent's total headcount by approximately 450 regular employees, representing approximately 2 percent of our global workforce. In the fourth quarter of fiscal year 2013, Agilent announced plans to separate the electronic measurement business from Agilent which is expected to be completed early in November 2014. As a result, approximately 50 employees from the targeted restructuring plan have been redeployed within the company, reducing the total headcount under this plan to 400 employees. The timing and scope of workforce reductions will vary based on local legal requirements. When completed, the restructuring program is expected to result in a reduction in annual cost of sales and operating expenses.

	As previously announced, we are streamlining our manufacturing operations. As part of this action, we anticipate the reduction of approximately 250 positions to reduce our annual cost of sales.

	Total headcount reductions from targeted restructuring and manufacturing streamlining will be approximately 650 positions. Within the U.S., we have substantially completed these restructuring activities. Internationally, we expect to complete the majority of these restructuring activities by the end of the second half of fiscal 2014. As of January 31, 2014, approximately 180 employees are pending termination under the above actions.

	A summary of total restructuring accrual activity is shown in the table below:



		Workforce
		Reduction
		(in millions)
	Balance as of October 31, 2013	$	24

	Income statement expense reversal	(4		)
	Cash payments	(8		)
	Balance as of January 31, 2014	$	12


	The restructuring reversal of $4 million recorded during the three months ended January 31, 2014 related to approximately 50 employees that have been redeployed within the company as a result of the separation announcement. The restructuring accruals which totaled $12 million at January 31, 2014, are recorded in other accrued liabilities on the condensed consolidated balance sheet. These balances reflect estimated future cash outlays.

	A summary of the activity in the condensed consolidated statement of operations resulting from all restructuring activities is shown below:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Cost of products and services	$	(1	)	$	—

	Research and development	(1		)	—

	Selling, general and administrative	(2		)	—

	Total restructuring and other related costs	$	(4	)	$	—

RETIREMENT_PLANS_AND_POST_RETI

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	3 Months Ended
	Jan. 31, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	'
	11. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

	Components of net periodic costs. For the three months ended January 31, 2014 and 2013, our net pension and post retirement benefit costs were comprised of the following:



		Pensions
		U.S. Plans						Non-U.S.						U.S. Post Retirement
								Plans						Benefit Plans
		Three Months Ended January 31,
		2014			2013			2014			2013			2014			2013
		(in millions)
	Service cost—benefits earned during the period	$	12		$	11		$	9		$	9		$	1		$	1

	Interest cost on benefit obligation	8			6			18			18			3			3

	Expected return on plan assets	(16		)	(13		)	(29		)	(25		)	(5		)	(5		)
	Amortization:
	Actuarial losses	—			3			11			14			3			5

	Prior service cost	(3		)	(3		)	—			—			(9		)	(9		)

	Total net plan costs	$	1		$	4		$	9		$	16		$	(7	)	$	(5	)





	We contributed approximately zero to our U.S. defined benefit plans and $17 million to our non-U.S. defined benefit plans during the three months ended January 31, 2014, respectively. We contributed approximately zero to our U.S. defined benefit plans and $12 million to our non-U.S. defined benefit plans during the three months ended January 31, 2013, respectively. We expect to contribute $30 million to our U.S. defined benefit plans during the remainder of 2014 and expect to contribute $55 million to our non-U.S. defined benefit plans during the remainder of 2014.

WARRANTIES_AND_CONTINGENCIES

WARRANTIES AND CONTINGENCIES	3 Months Ended
	Jan. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	12. WARRANTIES AND CONTINGENCIES

	Warranties

	We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend between one and three years from the date of delivery, depending on the product.

	A summary of the standard warranty accrual activity is shown in the table below:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Beginning balance as of November 1	$	69		$	60

	Accruals for warranties including change in estimate	24			22

	Settlements made during the period	(21		)	(20		)
	Ending balance as of January 31	$	72		$	62


	Accruals for warranties due within one year	$	50		$	52

	Accruals for warranties due after one year	22			10

	Ending balance as of January 31	$	72		$	62


	Contingencies

	We are involved in lawsuits, claims, investigations and proceedings, including patent, commercial and environmental matters. There are no matters pending that we currently believe are probable of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

	On March 4, 2013, we made a report to the Inspector General of the Department of Defense (“DOD IG”) regarding pricing irregularities relating to certain sales of electronic measurement products to U.S. government agencies. We have conducted a thorough investigation with the help of external counsel, and we have approached the DOD IG with a proposed methodology for resolving possible overcharges to U.S. government purchasers resulting from these sales. Based on our investigation and our interactions with the DOD IG, we do not believe that this matter is reasonably possible of having a material impact on Agilent's financial condition, results of operations or cash flows. As of January 31, 2014, we have accrued for this matter based on our current understanding.

	As part of routine internal audit activities, the Company determined that certain employees of Agilent's subsidiaries in China did not comply with the Company's Standards of Business Conduct and other policies. Based on those findings, the Company has initiated an internal investigation, with the assistance of outside counsel, relating to certain sales of our products through third party intermediaries in China. The internal investigation includes a review of compliance by our employees in China with the requirements of the U.S. Foreign Corrupt Practices Act and other applicable laws and regulations. On September 5, 2013, the Company voluntarily contacted the United States Securities and Exchange Commission and United States Department of Justice to advise both agencies of this internal investigation. We will cooperate with any government investigation of this matter. At this point, we cannot predict or estimate the duration, scope, cost, or result of this matter, or whether the government will commence any legal action, which could result in possible fines and penalties, criminal or civil sanctions, or other consequences. Accordingly, no provision with respect to these matters has been made in the Company's consolidated financial statements. Adverse findings or other negative outcomes from any governmental proceedings could have a material impact on the Company's consolidated financial statements in future periods.

SHORTTERM_DEBT

SHORT-TERM DEBT	3 Months Ended
SHORT-TERM DEBT	Jan. 31, 2014
Short-term Debt [Abstract]	'
SHORT-TERM DEBT	'
	13. SHORT-TERM DEBT

	Credit Facilities

	On October 20, 2011, we entered into a five-year credit agreement, which provides for a $400 million unsecured credit facility that will expire on October 20, 2016. The company may use amounts borrowed under the facility for general corporate purposes. As of January 31, 2014 the company had no borrowings outstanding under the facility. We were in compliance with the covenants for the credit facility during the three months ended January 31, 2014.

	As a result of the Dako acquisition, we have a credit facility in Danish Krone equivalent of $9 million with a Danish financial institution. No borrowings were outstanding under the facility as of January 31, 2014.

LONGTERM_DEBT

LONG-TERM DEBT	3 Months Ended
	Jan. 31, 2014
Debt Disclosure [Abstract]	'
LONG-TERM DEBT	'
	14. LONG-TERM DEBT

	Senior Notes

	The following table summarizes the company’s long-term senior notes and the related interest rate swaps:



		January 31, 2014						October 31, 2013
		Amortized Principal		Swap		Total		Amortized		Swap		Total
								Principal
		(in millions)
	2015 Senior Notes	$	500	$	11	$	511	$	500	$	12	$	512

	2017 Senior Notes	599		20		619		599		22		621

	2020 Senior Notes	498		25		523		498		26		524

	2022 Senior Notes	399		—		399		399		—		399

	2023 Senior Notes	597		—		597		597		—		597

	Total	$	2,593	$	56	$	2,649	$	2,593	$	60	$	2,653


	All notes are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the other senior notes, detailed in the table above, in the three months ended January 31, 2014 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2013. All swap contracts have been terminated and amounts to be amortized over the remaining life of the senior notes as of January 31, 2014 and October 31, 2013 are detailed above.

	Other Debt

	As of January 31, 2014, and as a result of the Dako acquisition, we have mortgage debt, secured on buildings in Denmark, in Danish Krone equivalent of $46 million aggregate principal outstanding with a Danish financial institution. The loan has a variable interest rate based on 3 months Copenhagen Interbank Rate ("Cibor") and will mature on September 30, 2027. Interest payments are made in March, June, September and December of each year.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Jan. 31, 2014
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS EQUITY	'
	15. STOCKHOLDERS' EQUITY

	Stock Repurchase Program

	On January 16, 2013, our board of directors approved a share-repurchase program (the "2013 repurchase program"). The 2013 repurchase program authorized the use of up to $500 million to repurchase shares of the company's common stock in open market transactions. On May 14, 2013, we announced that our board of directors authorized an increase of $500 million to the 2013 repurchase program bringing the cumulative authorization to $1 billion. As of January 31, 2014, there were no remaining amounts to be repurchased under the 2013 program.

	On November 22, 2013 we announced that our board of directors had authorized a new share repurchase program effective upon the conclusion of the company's $1 billion repurchase program. The new program is designed to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs to maintain a weighted average share count of approximately 335 million diluted shares. As of January 31, 2014, no share repurchases had been made under this program.

	For the three months ended January 31, 2014, we repurchased 2 million shares for $100 million. For the three months ended January 31, 2013, 2 million shares were repurchased for $79 million. All such shares and related costs are held as treasury stock and accounted for using the cost method.

	Cash Dividends on Shares of Common Stock

	During the three months ended January 31, 2014, we paid cash dividends of $0.132 per common share or $44 million on the company's common stock. During the three months ended January 31, 2013, we paid cash dividends of $0.10 per common share or $35 million on the company's common stock. In addition in the three months ended January 31, 2013, we declared cash dividends of $0.12 per common share or $42 million on the company's common stock.

	The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

	Accumulated Other Comprehensive Income

	Changes in accumulated comprehensive income by component and related tax effects for the three months ended January 31, 2014 were as follows (in millions):



											Net defined benefit pension cost and post retirement plan costs
			Unrealized gain on investments				Foreign currency translation				Prior service credits			Actuarial Losses			Unrealized gains (losses) on derivatives			Total
			(in millions)
	As of October 31, 2013		$	7			$	425			$	254		$	(595	)	$	—		$	91


	Other comprehensive income (loss) before reclassifications		(4		)		(60		)		—			—			(3		)	(67		)


	Amounts reclassified out of accumulated other comprehensive income		—				—				(12		)	17			1			6


	Tax (expense) benefit		1				5				4			(4		)	—			6


	Other comprehensive income (loss)		(3		)		(55		)		(8		)	13			(2		)	(55		)


	As of January 31, 2014		$	4			$	370			$	246		$	(582	)	$	(2	)	$	36



	Reclassifications out of accumulated comprehensive income for the three months ended January 31, 2014 and 2013 were as follows (in millions):


	Details about accumulated other		Amounts Reclassified								Affected line item in
	comprehensive income components		from other comprehensive income								statement of operations

			Three Months Ended
			January 31,
			2014				2013

	Unrealized gains and losses on derivatives		(1		)		1				Cost of products

			(1		)		1				Total before income tax

			1				—				Provision for income tax

			—				1				Total net of income tax

	Net defined benefit pension cost and post retirement plan costs:

Actuarial net loss		(17		)		(18		)
Prior service benefit		12				12

		(5		)		(6		)		Total before income tax
		—				—				Provision for income tax

		(5		)		(6		)		Total net of income tax

Total reclassfications for the period		$	(5	)		$	(5	)

Amounts in parentheses indicate reductions to income and increases to other comprehensive income.

Reclassfications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 11 "Retirement Plans and Post Retirement Pension Plans").

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Jan. 31, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	16. SEGMENT INFORMATION

	Description of segments. We are a measurement company providing core bio-analytical and electronic measurement solutions to the life sciences, diagnostics and genomics, chemical analysis, communications and electronics industries. In the fourth fiscal quarter of 2013, we formed a new operating segment from our existing businesses. The new life sciences and diagnostics segment was formed by the combination of the life sciences business plus the diagnostics and genomics business. Following this reorganization, Agilent has three business segments comprised of the life sciences and diagnostics business, the chemical analysis business and the electronic measurement business. The historical segment financial information for the life sciences and diagnostics segment has been recast to conform to this new reporting structure in our financial statements. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
	A description of our three reportable segments is as follows:
	Our life sciences and diagnostics business provides application-focused solutions that include reagents, instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Key product categories include: liquid chromatography (LC) systems, columns and components; liquid chromatography mass spectrometry (LCMS) systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; Nuclear Magnetic Resonance and X-Ray Diffraction systems; services and support for the aforementioned products; immunohistochemistry; In Situ Hybridization; Hematoxylin and Eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems. We also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also called companion diagnostics, with the potential of identifying patients most likely to benefit from a specific targeted therapy.
	Our chemical analysis business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Key product categories in chemical analysis include: gas chromatography (GC) systems, columns and components; gas chromatography mass spectrometry (GC-MS) systems; inductively coupled plasma mass spectrometry (ICP-MS) instruments; atomic absorption (AA) instruments; inductively coupled plasma optical emission spectrometry (ICP-OES) instruments; molecular spectroscopy instruments; software and data systems; vacuum pumps and measurement technologies; services and support for our products.

	Our electronic measurement business provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. We also offer customization, consulting and optimization services throughout the customer's product lifecycle.

	A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, real estate, insurance services, information technology services, treasury, other corporate infrastructure expenses and, historically, costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. Beginning in fiscal year 2014, we created the order fulfillment and supply chain organization (“OFS”) to centralize all order fulfillment and supply chain operations in our life sciences and diagnostics and chemicals analysis businesses. Similarly we created the order fulfillment and infrastructure (“OFI”) organization to centralize all order fulfillment and supply organizations and operations within our electronic measurement business. Both OFS and OFI provide resources for manufacturing, engineering and strategic sourcing to our respective businesses. In general, OFS and OFI employees are dedicated to specific businesses and the associated costs are directly allocated to those businesses.

	The following tables reflect the results of our reportable segments under our management reporting system. These results are not necessarily in conformity with U.S. GAAP. The performance of each segment is measured based on several metrics, including adjusted income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.

	The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, one-time and pre-separation costs, non-cash amortization and other items as noted in the reconciliations below.


		Life Sciences and Diagnostics				Chemical				Electronic			Total
						Analysis				Measurement
		(in millions)
	Three months ended January 31, 2014:

	Total net revenue	$	591			$	417			$	671		$	1,679

	Segment income from operations	$	100			$	94			$	102		$	296

	Three months ended January 31, 2013:

	Total net revenue	$	564			$	394			$	722		$	1,680

	Segment income from operations	$	82			$	81			$	125		$	288





	The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes:



		Three Months Ended
		January 31,
		2014				2013
		(in millions)
	Total reportable segments’ income from operations	$	296			$	288

	Restructuring	4				—

	Asset impairments	—				(1		)

	Transformational initiatives	(3		)		(3		)
	Amortization of intangibles	(51		)		(52		)
	Acquisition and integration costs	(7		)		(10		)
	Pre-separation costs	(20		)		—

	Other	(1		)		(5		)
	Interest income	2				2

	Interest expense	(29		)		(25		)
	Other income (expense), net	—				1

	Income before taxes, as reported	$	191			$	195


The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles, the valuation allowance relating to deferred tax assets and other assets.



	Life Sciences and Diagnostics				Chemical				Electronic			Total
					Analysis				Measurement
	(in millions)
Assets:

As of January 31, 2014	$	4,287			$	1,757			$	1,929		$	7,973

As of October 31, 2013	$	4,291			$	1,756			$	1,997		$	8,044

OVERVIEW_BASIS_OF_PRESENTATION1

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jan. 31, 2014
Accounting Policies [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $105 million and $112 million as of January 31, 2014 and October 31, 2013, respectively. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 8, "Fair Value Measurements" for additional information on the fair value of financial instruments.

Goodwill and Purchased Intangible Assets	'
	Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

	The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

	If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In October 2013, we combined the life sciences and diagnostics and genomics segments to form the life sciences and diagnostics segment. As a result, Agilent has three segments, life sciences and diagnostics, chemical analysis, and electronic measurement segments.

	In fiscal year 2013, we assessed goodwill impairment for our four reporting units which consisted of two segments: chemical analysis and electronic measurement; and two reporting units under the life sciences and diagnostics segment. The first of these two reporting units related to our life sciences business and the second related to our diagnostics business. We performed a qualitative test for goodwill impairment of the following three reporting units, as of September 30, 2013: the chemical analysis segment, the electronic measurement segment, and the reporting unit relating to life sciences. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these reporting units are greater than their respective carrying values. We performed a quantitative test for goodwill impairment of the reporting unit related to our diagnostics business as of September 30, 2013. Based on the results of our quantitative testing, the fair value was significantly in excess of the carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the three months ended January 31, 2014 and 2013.

	Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

	In July 2012, the FASB simplified the guidance for testing for impairment of indefinite-lived intangible assets other than goodwill. The changes are intended to reduce compliance costs. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The revised guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allowed the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value.

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Jan. 31, 2014
Share-based Compensation [Abstract]	'
Allocated Share-based compensation expense disclosure	'
	The impact on our results for share-based compensation was as follows:



		Three Months Ended

		January 31,

		2014			2013

		(in millions)
	Cost of products and services	$	8		$	8

	Research and development	6			4

	Selling, general and administrative	23			19

	Total share-based compensation expense	$	37		$	31


Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule	'

	The following assumptions were used to estimate the fair value of the options and LTPP grants.



		Three Months Ended
		January 31,
		2014		2013
	Stock Option Plans:

	Weighted average risk-free interest rate	1.7	%	0.9	%
	Dividend yield	1	%	1	%
	Weighted average volatility	39	%	39	%
	Expected life	5.8 yrs		5.8 yrs

	LTPP:
	Volatility of Agilent shares	36	%	37	%
	Volatility of selected peer-company shares	13%-57%		6%-64%

	Price-wise correlation with selected peers	47	%	49	%

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	3 Months Ended
	Jan. 31, 2014
Earnings Per Share [Abstract]	'
Reconciliation of the numerators and denominators of the basic and diluted net income per share	'
	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:



		Three Months Ended
		January 31,
		2014		2013
		(in millions)
	Numerator:

	Net income	$	195	$	179

	Denominator:
	Basic weighted-average shares	333		347

	Potentially dilutive common shares equivalents — stock options and other employee stock plans	5		5

	Diluted weighted-average shares	338		352

INVENTORY_Tables

INVENTORY (Tables)	3 Months Ended
	Jan. 31, 2014
Inventory, Net [Abstract]	'
INVENTORY	'
	INVENTORY



		January 31,		October 31,
		2014		2013
		(in millions)
	Finished goods	$	557	$	552

	Purchased parts and fabricated assemblies	531		514

	Inventory	$	1,088	$	1,066

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Jan. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill balances and movements for each reportable segments during the period	'
	The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2014:



		Life Sciences and Diagnostics			Chemical Analysis			Electronic			Total
								Measurement
		(in millions)
	Goodwill as of October 31, 2013	$	1,883		$	745		$	419		$	3,047

	Foreign currency translation impact	(13		)	(8		)	(9		)	(30		)
	Goodwill arising from acquisitions/adjustments	—			—			—			—

	Goodwill as of January 31, 2014	$	1,870		$	737		$	410		$	3,017


Components of other intangibles during the period	'

	The components of other intangibles as of January 31, 2014 and October 31, 2013 are shown in the table below:



		Purchased Other Intangible Assets
		Gross			Accumulated			Net Book
		Carrying			Amortization			Value
		Amount			and
					Impairments
		(in millions)
	As of October 31, 2013:

	Purchased technology	$	1,019		$	460		$	559

	Backlog	14			14			—

	Trademark/Tradename	176			40			136

	Customer relationships	401			215			186

	Total amortizable intangible assets	1,610			729			881

	In-Process R&D	35			—			35

	Total	$	1,645		$	729		$	916

	As of January 31, 2014:

	Purchased technology	1,020			493			527

	Backlog	14			14			—

	Trademark/Tradename	176			44			132

	Customer relationships	398			229			169

	Total amortizable intangible assets	1,608			780			828

	In-Process R&D	31			—			31

	Total	$	1,639		$	780		$	859

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Jan. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Assets And Liabilities Measured On Recurring Basis	'
	Assets and liabilities measured at fair value on a recurring basis as of January 31, 2014 were as follows:



					Fair Value Measurement at January 31, 2014 Using
		January 31,			Quoted Prices			Significant			Significant
		2014			in Active			Other			Unobservable
					Markets for			Observable			Inputs
					Identical Assets			Inputs			(Level 3)
					(Level 1)			(Level 2)
		(in millions)
	Assets:

	Short-term

	Cash equivalents (money market funds)	$	2,080		$	2,080		$	—		$	—

	Derivative instruments (foreign exchange contracts)	8			—			8			—

	Long-term
	Trading securities	46			46			—			—

	Available-for-sale investments	22			22			—			—

	Total assets measured at fair value	$	2,156		$	2,148		$	8		$	—

	Liabilities:

	Short-term
	Derivative instruments (foreign exchange contracts)	$	16		$	—		$	16		$	—

	Long-term
	Deferred compensation liability	46			—			46			—

	Total liabilities measured at fair value	$	62		$	—		$	62		$	—

	Assets and liabilities measured at fair value on a recurring basis as of October 31, 2013 were as follows:



					Fair Value Measurement at October 31, 2013 Using
		October 31,			Quoted Prices			Significant			Significant
		2013			in Active			Other			Unobservable
					Markets for			Observable			Inputs
					Identical Assets			Inputs			(Level 3)
					(Level 1)			(Level 2)
		(in millions)
	Assets:

	Short-term

	Cash equivalents (money market funds)	$	1,968		$	1,968		$	—		$	—

	Derivative instruments (foreign exchange contracts)	7			—			7			—

	Long-term
	Trading securities	51			51			—			—

	Available-for-sale investments	25			25			—			—

	Total assets measured at fair value	$	2,051		$	2,044		$	7		$	—

	Liabilities:

Short-term
Derivative instruments (foreign exchange contracts)	$	6		$	—		$	6		$	—

Long-term
Deferred compensation liability	51			—			51			—

Total liabilities measured at fair value	$	57		$	—		$	57		$	—


Impairment of Long-lived assets included in net income	'
	For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income during the three months ended January 31, 2014 and 2013:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Long-lived assets held and used	$	—		$	—

	Long-lived assets held for sale	$	—		$	1

DERIVATIVES_Tables

DERIVATIVES (Tables)	3 Months Ended
	Jan. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Aggregated notional amounts by currency and designation	'
	The aggregated notional amounts by currency and designation as of January 31, 2014 were as follows:



			Derivatives in Cash Flow							Derivatives
			Hedging Relationships							Not
										Designated
										as Hedging
										Instruments
			Forward				Option			Forward
			Contracts				Contracts			Contracts
	Currency		Buy/(Sell)				Buy/(Sell)			Buy/(Sell)
			(in millions)
	Euro		$	(30	)		$	—		$	167

	British Pound		(14		)		—			2

	Canadian Dollar		(35		)		—			—

	Australian Dollars		12				—			6

	Malaysian Ringgit		108				—			10

	Japanese Yen		(62		)		(83		)	(19		)
	Other		(15		)		—			(21		)

	Totals		$	(36	)		$	(83	)	$	145


Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	'
	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of January 31, 2014 and October 31, 2013 were as follows:



	Fair Values of Derivative Instruments
	Asset Derivatives									Liability Derivatives
			Fair Value									Fair Value
	Balance Sheet Location		January 31,				October 31,			Balance Sheet Location		January 31,		October 31,
			2014				2013					2014		2013
	(in millions)
	Derivatives designated as hedging instruments:

	Cash flow hedges
	Foreign exchange contracts
	Other current assets		$	5			$	4		Other accrued liabilities		$	7	$	4

	Derivatives not designated as hedging instruments:

	Foreign exchange contracts

	Other current assets		$	3			$	3		Other accrued liabilities		$	9	$	2

	Total derivatives		$	8			$	7				$	16	$	6

Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	'
	The effect of derivative instruments for interest rate swap contracts and foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:




		Three Months Ended
		January 31,
		2014				2013
		(in millions)
	Derivatives designated as hedging instruments:

	Cash Flow Hedges
	Foreign exchange contracts:
	Gain (loss) recognized in accumulated other comprehensive income	$	(3	)		$	8

	Gain (loss) reclassified from accumulated other comprehensive income into cost of sales	$	(1	)		$	1

	Derivatives not designated as hedging instruments:
	Gain (loss) recognized in other income (expense)	$	(1	)		$	3

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	3 Months Ended
	Jan. 31, 2014
Restructuring and Related Activities [Abstract]	'
Summary of total restructuring activity	'
	A summary of total restructuring accrual activity is shown in the table below:



		Workforce
		Reduction
		(in millions)
	Balance as of October 31, 2013	$	24

	Income statement expense reversal	(4		)
	Cash payments	(8		)
	Balance as of January 31, 2014	$	12

Restructuring by statement of operations caption	'

	A summary of the activity in the condensed consolidated statement of operations resulting from all restructuring activities is shown below:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Cost of products and services	$	(1	)	$	—

	Research and development	(1		)	—

	Selling, general and administrative	(2		)	—

	Total restructuring and other related costs	$	(4	)	$	—

RETIREMENT_PLANS_AND_POST_RETI1

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	3 Months Ended
	Jan. 31, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Schedule of net pension and post-retirement benefit costs	'
	Components of net periodic costs. For the three months ended January 31, 2014 and 2013, our net pension and post retirement benefit costs were comprised of the following:



		Pensions
		U.S. Plans						Non-U.S.						U.S. Post Retirement
								Plans						Benefit Plans
		Three Months Ended January 31,
		2014			2013			2014			2013			2014			2013
		(in millions)
	Service cost—benefits earned during the period	$	12		$	11		$	9		$	9		$	1		$	1

	Interest cost on benefit obligation	8			6			18			18			3			3

	Expected return on plan assets	(16		)	(13		)	(29		)	(25		)	(5		)	(5		)
	Amortization:
	Actuarial losses	—			3			11			14			3			5

	Prior service cost	(3		)	(3		)	—			—			(9		)	(9		)

	Total net plan costs	$	1		$	4		$	9		$	16		$	(7	)	$	(5	)

WARRANTIES_AND_CONTINGENCIES_T

WARRANTIES AND CONTINGENCIES (Tables)	3 Months Ended
	Jan. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Standard warranty	'
	A summary of the standard warranty accrual activity is shown in the table below:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Beginning balance as of November 1	$	69		$	60

	Accruals for warranties including change in estimate	24			22

	Settlements made during the period	(21		)	(20		)
	Ending balance as of January 31	$	72		$	62


	Accruals for warranties due within one year	$	50		$	52

	Accruals for warranties due after one year	22			10

	Ending balance as of January 31	$	72		$	62

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	3 Months Ended
	Jan. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Interest Rate Swaps pertaining to Senior Notes offered	'
	The following table summarizes the company’s long-term senior notes and the related interest rate swaps:



		January 31, 2014						October 31, 2013
		Amortized Principal		Swap		Total		Amortized		Swap		Total
								Principal
		(in millions)
	2015 Senior Notes	$	500	$	11	$	511	$	500	$	12	$	512

	2017 Senior Notes	599		20		619		599		22		621

	2020 Senior Notes	498		25		523		498		26		524

	2022 Senior Notes	399		—		399		399		—		399

	2023 Senior Notes	597		—		597		597		—		597

	Total	$	2,593	$	56	$	2,649	$	2,593	$	60	$	2,653

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Jan. 31, 2014
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	Changes in accumulated comprehensive income by component and related tax effects for the three months ended January 31, 2014 were as follows (in millions):



								Net defined benefit pension cost and post retirement plan costs
		Unrealized gain on investments			Foreign currency translation			Prior service credits			Actuarial Losses			Unrealized gains (losses) on derivatives			Total
		(in millions)
	As of October 31, 2013	$	7		$	425		$	254		$	(595	)	$	—		$	91


	Other comprehensive income (loss) before reclassifications	(4		)	(60		)	—			—			(3		)	(67		)


	Amounts reclassified out of accumulated other comprehensive income	—			—			(12		)	17			1			6


	Tax (expense) benefit	1			5			4			(4		)	—			6


	Other comprehensive income (loss)	(3		)	(55		)	(8		)	13			(2		)	(55		)


	As of January 31, 2014	$	4		$	370		$	246		$	(582	)	$	(2	)	$	36

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
	Reclassifications out of accumulated comprehensive income for the three months ended January 31, 2014 and 2013 were as follows (in millions):


	Details about accumulated other	Amounts Reclassified						Affected line item in
	comprehensive income components	from other comprehensive income						statement of operations

		Three Months Ended
		January 31,
		2014			2013

	Unrealized gains and losses on derivatives	(1		)	1			Cost of products

		(1		)	1			Total before income tax

		1			—			Provision for income tax

		—			1			Total net of income tax

	Net defined benefit pension cost and post retirement plan costs:

	Actuarial net loss	(17		)	(18		)
	Prior service benefit	12			12

		(5		)	(6		)	Total before income tax
		—			—			Provision for income tax

		(5		)	(6		)	Total net of income tax

	Total reclassfications for the period	$	(5	)	$	(5	)

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
	Jan. 31, 2014
Segment Reporting [Abstract]	'
Segment Profitability and Segment Assets	'
	The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, one-time and pre-separation costs, non-cash amortization and other items as noted in the reconciliations below.


		Life Sciences and Diagnostics			Chemical			Electronic		Total
					Analysis			Measurement
		(in millions)
	Three months ended January 31, 2014:

	Total net revenue	$	591		$	417		$	671	$	1,679

	Segment income from operations	$	100		$	94		$	102	$	296

	Three months ended January 31, 2013:

	Total net revenue	$	564		$	394		$	722	$	1,680

	Segment income from operations	$	82		$	81		$	125	$	288





	The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles, the valuation allowance relating to deferred tax assets and other assets.



		Life Sciences and Diagnostics			Chemical			Electronic		Total
					Analysis			Measurement
		(in millions)
	Assets:

	As of January 31, 2014	$	4,287		$	1,757		$	1,929	$	7,973

	As of October 31, 2013	$	4,291		$	1,756		$	1,997	$	8,044


Reconciliation of segment results to total enterprise results	'
	The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes:



		Three Months Ended
		January 31,
		2014			2013
		(in millions)
	Total reportable segments’ income from operations	$	296		$	288

	Restructuring	4			—

	Asset impairments	—			(1		)

	Transformational initiatives	(3		)	(3		)
	Amortization of intangibles	(51		)	(52		)
	Acquisition and integration costs	(7		)	(10		)
	Pre-separation costs	(20		)	—

	Other	(1		)	(5		)
	Interest income	2			2

	Interest expense	(29		)	(25		)
	Other income (expense), net	—			1

	Income before taxes, as reported	$	191		$	195

OVERVIEW_BASIS_OF_PRESENTATION2

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Oct. 31, 2013
	M		segment
	Y
Fair Value of Financial Instruments	'	'	'
Fair value of our long-term debt exceeds the carrying value	$105	$112	'
Goodwill and Purchased Intangible Assets	'	'	'
Number of operating segments	'	'	3
Purchased intangible assets useful life range minimum (in months)	6	'	'
Purchased intangible assets useful life range maximum (in years)	15	'	'
Impairment of goodwill	0	0	'
Impairment of intangible assets (IPR&D)	$0	$0	'

SHAREBASED_COMPENSATION_Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]	'	'
Share-based compensation expense	$37	$31
Windfall tax benefit realized	3	2
Share-based compensation capitalized within inventory	2	'
Cost of Products and Services [Member]	'	'
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]	'	'
Share-based compensation expense	8	8
Research and Development Expense [Member]	'	'
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]	'	'
Share-based compensation expense	6	4
Selling, General and Administrative Expenses [Member]	'	'
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]	'	'
Share-based compensation expense	$23	$19

SHAREBASED_COMPENSATION_Fair_V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	3 Months Ended
SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	Jan. 31, 2014	Jan. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
ESPP plan purchase price (in hundredths)	85.00%	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average risk-free interest rate (in hundredths)	1.70%	0.90%
Dividend yield	1.00%	1.00%
Weighted average volatility (in hundredths)	39.00%	39.00%
Expected life (in years)	'5 years 9 months 18 days	'5 years 9 months 18 days
LTPP [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility of Agilent shares (in hundredths)	36.00%	37.00%
Volatility of selected peer-company shares minimum (in hundredths)	13.00%	6.00%
Volatility of selected peer-company shares maximum (in hundredths)	57.00%	64.00%
Price-wise correlation with selected peers (in hundredths)	47.00%	49.00%

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Income Tax Examination [Line Items]	'	'
Effective Income Tax Rate Reconciliation, Percent	-2.00%	8.20%
Income Tax Expense (Benefit)	($4)	$16
Net Discrete Tax Benefit	35	11
Tax liabilities on foreign earnings distributions	125	'
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	160	'
Internal Revenue Service (IRS) [Member]	'	'
Income Tax Examination [Line Items]	'	'
Unrecognized tax benefits, decrease resulting from error in adoption of Fin 48	$65	'

NET_INCOME_PER_SHARE_Details

NET INCOME PER SHARE (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Denominators:	'	'
Basic weighted-average shares (in shares)	333,000,000	347,000,000
Potentially dilutive common shares equivalents - stock options and other employee stock plans (in shares)	5,000,000	5,000,000
Diluted weighted average shares (in shares)	338,000,000	352,000,000
Numerator:	'	'
Net Income	$195	$179
Options with exercise price greater than average market price [Member]	'	'
Antidilutive Securities Excluded from EPS Computation	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	5,600
Stock Options, LTPP and restricted stock combined exercise price, unamortized fair value, excess tax benefits or shortfalls greater than average market price [Member] [Member]	'	'
Antidilutive Securities Excluded from EPS Computation	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	20,000

INVENTORY_Details

INVENTORY (Details) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Inventory, Net [Abstract]	'	'
Finished goods	$557	$552
Purchased parts and fabricated assemblies	531	514
Inventory	$1,088	$1,066

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Goodwill [Roll Forward]	'	'
Goodwill beginning balance	$3,047	'
Foreign currency translation impact	-30	'
Goodwill arising from acquisitions/adjustments	0	10
Goodwill ending balance	3,017	'
Life Sciences and Diagnostics [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill beginning balance	1,883	'
Foreign currency translation impact	-13	'
Goodwill arising from acquisitions/adjustments	0	'
Goodwill ending balance	1,870	'
Chemical Analysis [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill beginning balance	745	'
Foreign currency translation impact	-8	'
Goodwill arising from acquisitions/adjustments	0	'
Goodwill ending balance	737	'
Electronic Measurement [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill beginning balance	419	'
Foreign currency translation impact	-9	'
Goodwill arising from acquisitions/adjustments	0	'
Goodwill ending balance	$410	'

GOODWILL_AND_OTHER_INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	$1,639	$1,645
Accumulated Amortization and Impairments	780	729
Net Book Value	859	916
Purchased technology [Member]	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	1,020	1,019
Accumulated Amortization and Impairments	493	460
Net Book Value	527	559
Backlog [Member]	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	14	14
Accumulated Amortization and Impairments	14	14
Net Book Value	0	0
Trademark/Tradenames [Member]	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	176	176
Accumulated Amortization and Impairments	44	40
Net Book Value	132	136
Customer relationships [Member]	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	398	401
Accumulated Amortization and Impairments	229	215
Net Book Value	169	186
In Process R And D [Member]	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]	'	'
In-Process R&D	31	35
Total amortizable intangible assets [Member]	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'
Gross Carrying Amount	1,608	1,610
Accumulated Amortization and Impairments	780	729
Net Book Value	$828	$881

GOODWILL_AND_OTHER_INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Additions to goodwill	$0	$10
Additions to other intangibles	0	1
Foreign exchange translation impact	-7	33
In-process research and development Increase Decrease	4	22
Amortization of intangible assets during the period	$51	$51

GOODWILL_AND_OTHER_INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Finite-Lived Assets Future Amortization Expense (Details) (USD $)	Jan. 31, 2014
In Millions, unless otherwise specified	Jan. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'
Future amortization expense for remainder of 2013	$143
Future amortization expense for 2014	181
Future amortization expense for 2015	154
Future amortization expense for 2016	106
Future amortization expense for 2017	70
Future amortization expense for 2018	55
Future amortization thereafter	$119

FAIR_VALUE_MEASUREMENTS_Fair_v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Oct. 31, 2013	Jan. 31, 2014	Oct. 31, 2013	Jan. 31, 2014	Oct. 31, 2013	Jan. 31, 2014	Oct. 31, 2013
			Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]
					Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Significant Other Observable Inputs (Level 2) [Member]	Significant Other Observable Inputs (Level 2) [Member]	Significant Unobservable Inputs (Level 3) [Member]	Significant Unobservable Inputs (Level 3) [Member]
Assets Short - term [Abstract]	'	'	'	'	'	'	'	'	'	'
Cash equivalents (money market funds)	'	'	$2,080	$1,968	$2,080	$1,968	$0	$0	$0	$0
Derivative instruments (foreign exchange contracts)	'	'	8	7	0	0	8	7	0	0
Assets, Long-term [Abstract]	'	'	'	'	'	'	'	'	'	'
Trading securities	'	'	46	51	46	51	0	0	0	0
Available-for-sale investments	'	'	22	25	22	25	0	0	0	0
Total assets measured at fair value	'	'	2,156	2,051	2,148	2,044	8	7	0	0
Liabilities, Short-term [Abstract]	'	'	'	'	'	'	'	'	'	'
Derivative instruments (foreign exchange contracts)	'	'	16	6	0	0	16	6	0	0
Liabilities Long-term [Abstract]	'	'	'	'	'	'	'	'	'	'
Deferred compensation liability	'	'	46	51	0	0	46	51	0	0
Total liabilities measured at fair value	'	'	62	57	0	0	62	57	0	0
Impairment of Investments	'	'	'	'	'	'	'	'	'	'
Impairment of Investments	$0	$0	'	'	'	'	'	'	'	'

FAIR_VALUE_MEASUREMENTS_Fair_v1

FAIR VALUE MEASUREMENTS, Fair value measures and impairment of long-lived assets (Details) (Fair Value, Measurements, Nonrecurring [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Long-Lived Assets [Abstract]	'	'
Impairment long-lived assets held and used	$0	$0
Impairment long-lived assets held for sale	0	1
Carrying value [Member]	'	'
Long-Lived Assets [Abstract]	'	'
Long-lived assets held for sale	'	3
Fair value [Member]	'	'
Long-Lived Assets [Abstract]	'	'
Long-lived assets held for sale	'	$2

DERIVATIVES_Details

DERIVATIVES (Details) (USD $)	Jan. 31, 2014	Sep. 10, 2012	Jan. 31, 2014	Jun. 06, 2011	Jan. 31, 2014	Aug. 09, 2011	Jan. 31, 2014	Nov. 25, 2008	Jul. 01, 2012
In Millions, unless otherwise specified	contracts		Senior Notes 2015	Senior Notes 2015	Senior Notes 2020	Senior Notes 2020	Senior Notes 2017	Senior Notes 2017	Treasury Lock [Member]
				contracts		contracts		contracts	Cash Flow Hedging [Member]
Terminated Interest Rate Swaps	'	'	'	'	'	'	'	'	'
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated (in units)	'	'	'	5	'	5	'	2	'
Notional Amount of Terminated Interest Rate Swaps	'	'	'	$500	'	$500	'	$400	'
Amount to be amortized on terminated interest rates swaps	'	'	11	'	25	'	20	'	'
Derivative Instruments and Hedging Activities Disclosure	'	'	'	'	'	'	'	'	'
Notional Amount of Interest Rate Swap Contract Designated as Cash Flow Hedges	'	'	'	'	'	'	'	'	400
Amount to be amortized on terminated cash flow hedge	'	3	'	'	'	'	'	'	'
Aggregate Fair Value of all Derivative Instruments with Credit-Risk-Related Contingent Features that were in a Net Liability Position	$11	'	'	'	'	'	'	'	'
Derivative Contracts [Abstract]	'	'	'	'	'	'	'	'	'
Foreign exchange forward contracts designated as cash flow hedge (in units)	135	'	'	'	'	'	'	'	'
Foreign exchange option contracts designated as cash flow hedge (in units)	16	'	'	'	'	'	'	'	'
Foreign exchange forward contracts not designated as hedges (in units)	181	'	'	'	'	'	'	'	'

DERIVATIVES_Disclosures_and_de

DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) (USD $)	Jan. 31, 2014
In Millions, unless otherwise specified	Jan. 31, 2014
Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	$145
Derivatives Not Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Danish Krone sell Euro	70
Danish Krone sell Japanese Yen	5
Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-36
Derivatives Designated as Hedging Instruments [Member] \| Option Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-83
Sell [Member] \| Euro [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-30
Sell [Member] \| British Pound [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-14
Sell [Member] \| Canadian Dollar [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-35
Sell [Member] \| Japanese Yen [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	-19
Sell [Member] \| Japanese Yen [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-62
Sell [Member] \| Japanese Yen [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Option Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-83
Sell [Member] \| Other [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	-21
Sell [Member] \| Other [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	-15
Buy [Member] \| Euro [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	167
Buy [Member] \| British Pound [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	2
Buy [Member] \| Australian Dollars [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	6
Buy [Member] \| Australian Dollars [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	12
Buy [Member] \| Malaysian Ringgit [Member] \| Forward Contracts Buy/(Sell) [Member] \| Derivatives Not Designated as Hedging Instruments [Member]	'
Derivative [Line Items]	'
Total notional amount	10
Buy [Member] \| Malaysian Ringgit [Member] \| Derivatives Designated as Hedging Instruments [Member] \| Forward Contracts Buy/(Sell) [Member]	'
Derivative [Line Items]	'
Total notional amount	$108

DERIVATIVES_Fair_value_of_deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Derivative Fair Value by Balance Sheet Location [Abstract]	'	'
Total derivatives Asset	$8	$7
Total derivatives Liabilities	16	6
Derivatives Not Designated as Hedging Instruments [Member] \| Foreign Exchange Contracts [Member] \| Other Current Assets [Member]	'	'
Derivative Fair Value by Balance Sheet Location [Abstract]	'	'
Total derivatives Asset	3	3
Derivatives Not Designated as Hedging Instruments [Member] \| Foreign Exchange Contracts [Member] \| Other Accrued Liabilities [Member]	'	'
Derivative Fair Value by Balance Sheet Location [Abstract]	'	'
Total derivatives Liabilities	9	2
Derivatives Designated as Hedging Instruments [Member] \| Cash Flow Hedging [Member] \| Foreign Exchange Contracts [Member] \| Other Current Assets [Member]	'	'
Derivative Fair Value by Balance Sheet Location [Abstract]	'	'
Total derivatives Asset	5	4
Derivatives Designated as Hedging Instruments [Member] \| Cash Flow Hedging [Member] \| Foreign Exchange Contracts [Member] \| Other Accrued Liabilities [Member]	'	'
Derivative Fair Value by Balance Sheet Location [Abstract]	'	'
Total derivatives Liabilities	$7	$4

DERIVATIVES_Effect_of_derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Derivative [Line Items]	'	'
Gain (loss) recognized in accumulated other comprehensive income	($3)	'
Designated as Hedging Instrument [Member] \| Cash Flow Hedging [Member] \| Foreign Exchange Contracts [Member] \| Accumulated Other Comprehensive Income (Loss) [Member]	'	'
Derivative [Line Items]	'	'
Gain (loss) recognized in accumulated other comprehensive income	-3	8
Designated as Hedging Instrument [Member] \| Cash Flow Hedging [Member] \| Foreign Exchange Contracts [Member] \| Cost of Sales [Member]	'	'
Derivative [Line Items]	'	'
Gain (loss) reclassified from accumulated other comprehensive income into cost of sales	-1	1
Derivatives Not Designated as Hedging Instruments [Member] \| Other income (expense) [Member]	'	'
Derivative [Line Items]	'	'
Gain (loss) recognized in other income (expense)	-1	3
Cash Flow Hedging [Member] \| Cost of Sales [Member]	'	'
Derivative [Line Items]	'	'
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	$3	'

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Restructuring Plan [Abstract]	'	'
Expected number of positions to be eliminated	650	'
Restructuring Reserve Roll Forward[Abstract]	'	'
Restructuring charges (reversals)	($4)	$0
Number of Employees Pending Termination	180	'
Targeted Restructuring Plan [Member]	'	'
Restructuring Plan [Abstract]	'	'
Initial expected number of positions to be eliminated	450	'
Reduction in the expected number of positions to be eliminated	50	'
Expected number of positions to be eliminated	400	'
Workforce reduction as a percent of total headcount	2.00%	'
Manufacturing Streamlining [Member]	'	'
Restructuring Plan [Abstract]	'	'
Expected number of positions to be eliminated	250	'
Workforce Reduction [Member]	'	'
Restructuring Reserve Roll Forward[Abstract]	'	'
Beginning balance	24	'
Restructuring charges (reversals)	-4	'
Cash payments	-8	'
Ending balance	12	'
Restructuring accrual	$12	'

RESTRUCTURING_Income_Statement

RESTRUCTURING Income Statement Location (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Restructuring	'	'
Restructuring charges (reversals)	($4)	$0
Cost of Products and Services [Member]	'	'
Restructuring	'	'
Restructuring charges (reversals)	-1	0
Research and Development Expense [Member]	'	'
Restructuring	'	'
Restructuring charges (reversals)	-1	0
Selling, General and Administrative Expenses [Member]	'	'
Restructuring	'	'
Restructuring charges (reversals)	($2)	$0

RETIREMENT_PLANS_AND_POST_RETI2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Pensions (U.S. Plans) [Member]	'	'
Defined Benefit Plan, Net Periodic Benefit Cost	'	'
Service cost - benefits earned during the period	$12	$11
Interest cost on benefit obligation	8	6
Expected return on plan assets	-16	-13
Amortization:	'	'
Actuarial losses	0	3
Prior service cost	-3	-3
Total net plan costs	1	4
Pensions (Non-U.S. Plans) [Member]	'	'
Defined Benefit Plan, Net Periodic Benefit Cost	'	'
Service cost - benefits earned during the period	9	9
Interest cost on benefit obligation	18	18
Expected return on plan assets	-29	-25
Amortization:	'	'
Actuarial losses	11	14
Prior service cost	0	0
Total net plan costs	9	16
United States Postretirement Benefit Plan [Member]	'	'
Defined Benefit Plan, Net Periodic Benefit Cost	'	'
Service cost - benefits earned during the period	1	1
Interest cost on benefit obligation	3	3
Expected return on plan assets	-5	-5
Amortization:	'	'
Actuarial losses	3	5
Prior service cost	-9	-9
Total net plan costs	($7)	($5)

RETIREMENT_PLANS_AND_POST_RETI3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Pensions (U.S. Plans) [Member]	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Contributions to defined benefit plans	$0	$0
Estimated future employer contributions in remainder of current fiscal year	30	'
Pensions (Non-U.S. Plans) [Member]	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Contributions to defined benefit plans	17	12
Estimated future employer contributions in remainder of current fiscal year	$55	'

WARRANTIES_AND_CONTINGENCIES_D

WARRANTIES AND CONTINGENCIES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'
Beginning balance at beginning of period	$69	$60
Accruals for warranties including change in estimate issued during the period	24	22
Settlements made during the period	-21	-20
Ending balance at end of period	72	62
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]	'	'
Accruals for warranties due within one year	50	52
Accruals for warranties due after one year	22	10
Ending balance at end of period	$72	$62

SHORTTERM_DEBT_Credit_Facility

SHORT-TERM DEBT Credit Facility (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014
Line of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Initiation Date	20-Oct-11
Short-term Debt, Terms (in years)	'five
Line Of Credit Facility Initial Maximum Borrowing Capacity	$400
Line of Credit Facility, Expiration Date	20-Oct-16
Line of Credit Facility, Amount Outstanding	0
Dako [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	9
Line of Credit Facility, Amount Outstanding	$0

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Debt Instrument	'	'
Amortized Principal	$2,593	$2,593
Interest Rate Swap	56	60
Carrying Value of Senior Notes	2,649	2,653
Senior Notes 2015	'	'
Debt Instrument	'	'
Long-term Debt	500	500
Interest Rate Swap	11	12
Carrying Value of Senior Notes	511	512
Senior Notes 2017	'	'
Debt Instrument	'	'
Long-term Debt	599	599
Interest Rate Swap	20	22
Carrying Value of Senior Notes	619	621
Senior Notes 2020	'	'
Debt Instrument	'	'
Long-term Debt	498	498
Interest Rate Swap	25	26
Carrying Value of Senior Notes	523	524
Senior Notes 2022	'	'
Debt Instrument	'	'
Long-term Debt	399	399
Interest Rate Swap	0	0
Carrying Value of Senior Notes	399	399
Senior Notes 2023 [Member]	'	'
Debt Instrument	'	'
Long-term Debt	597	597
Interest Rate Swap	0	0
Carrying Value of Senior Notes	$597	$597

LONGTERM_DEBT_LongTerm_Debt_Se

LONG-TERM DEBT Long-Term Debt - Senior Notes and Other Debt (Details) (USD $)	Jan. 31, 2014
In Millions, unless otherwise specified	Jan. 31, 2014
Other Long-term Debt	'
Mortgage Loans on Real Estate	$46

STOCKHOLDERS_EQUITY_Stock_Repu

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) (USD $)	3 Months Ended		0 Months Ended		3 Months Ended		0 Months Ended	3 Months Ended
Share data in Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	14-May-13	Jan. 16, 2013	Jan. 31, 2014	Jan. 31, 2013	Nov. 22, 2013	Jan. 31, 2014	Jan. 16, 2013
	Jan. 31, 2014	Jan. 31, 2013	2013 Share Repurchase Program	2013 Share Repurchase Program	2013 Share Repurchase Program	2013 Share Repurchase Program	2014 Share Repurchase Program [Member]	2014 Share Repurchase Program [Member]	2014 Share Repurchase Program [Member]
Share Repurchase Program [Line Items]	'	'	'	'	'	'	'	'	'
Share repurchase program approval date	'	'	'	'January 16, 2013	'	'	'	'	'November 22, 2013
Initial amount authorized	'	'	'	$500,000,000	'	'	'	'	'
Increase amount authorized	'	'	500,000,000	'	'	'	'	'	'
New authorized amount	'	'	1,000,000,000	'	'	'	1,000,000,000	'	'
Remaining authorized repurchase amount	'	'	'	'	0	'	'	'	'
Maintain weighted average diluted shares count	'	'	'	'	'	'	335	'	'
Cost to repurchases shares of common stock under share repurchase program	$100,000,000	$79,000,000	'	'	$100,000,000	$79,000,000	'	'	'
Number of shares repurchased (in shares)	'	'	'	'	2	2	'	0	'

STOCKHOLDERS_EQUITY_Dividends_

STOCKHOLDER"S EQUITY - Dividends (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Dividends Paid [Abstract]	'	'
Cash paid per share for dividends previously declared	$0.13	$0.10
Aggregate cash paid for dividends previously declared	$44	$35
Common Stock, Dividends, Per Share, Declared	'	$0.12
Dividends, Common Stock, Cash	'	$42

STOCKHOLDERS_EQUITY_Accumulate

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
As of October 31, 2013	$91	'
Other comprehensive income (loss) before reclassifications	-67	'
Amounts reclassified out of accumulated other comprehensive income	6	'
Tax (expense) benefit	6	'
Other comprehensive income (loss)	-55	70
As of January 31, 2014	36	'
Unrealized gain on investments [Abstract]	'	'
As of October 31, 2013	7	'
Other comprehensive income (loss) before reclassifications	-4	'
Amounts reclassified out of accumulated other comprehensive income	0	'
Tax (expense) benefit	1	-2
Other comprehensive income (loss)	-3	'
As of January 31, 2014	4	'
Foreign currency translation [Abstract]	'	'
As of October 31, 2013	425	'
Other comprehensive income (loss) before reclassifications	-60	'
Amounts reclassified out of accumulated other comprehensive income	0	'
Tax (expense) benefit	5	0
Other comprehensive income (loss)	-55	'
As of January 31, 2014	370	'
Prior service credits [Abstract]	'	'
As of October 31, 2013	254	'
Other comprehensive income (loss) before reclassifications	0	'
Amounts reclassified out of accumulated other comprehensive income	-12	-12
Tax (expense) benefit	4	'
Other comprehensive income (loss)	-8	-8
As of January 31, 2014	246	'
Actuarial Losses [Abstract]	'	'
As of October 31, 2013	-595	'
Other comprehensive income (loss) before reclassifications	0	'
Amounts reclassified out of accumulated other comprehensive income	17	18
Tax (expense) benefit	-4	-4
Other comprehensive income (loss)	13	14
As of January 31, 2014	-582	'
Unrealized gains (losses) on derivatives [Abstract]	'	'
As of October 31, 2013	0	'
Other comprehensive income (loss) before reclassifications	-3	'
Amounts reclassified out of accumulated other comprehensive income	-1	'
Tax (expense) benefit	0	'
Other comprehensive income (loss)	-2	'
As of January 31, 2014	($2)	'

STOCKHOLDERS_EQUITY_Reclassifi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Unrealized gains and losses on derivatives reclassified to cost of products	($1)	$1
Tax on unrealized gains and losses on derivatives reclassified to cost of products	1	0
Unrealized gains and losses on derivatives reclassified to cost of products, net of tax	0	1
Actuarial net loss	-17	-18
Prior service benefit	12	12
Actuarial net loss and prior service benefit reclassified, before tax	-5	-6
Tax on actuarial net loss and prior service benefit reclassified	0	0
Actuarial net loss and prior service benefit reclassified, net of tax	-5	-6
Total reclassification for the period	($5)	($5)

SEGMENT_INFORMATION_Profitabil

SEGMENT INFORMATION Profitability (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Oct. 31, 2013
	Jan. 31, 2014	Jan. 31, 2013	segment
Segment Reporting [Abstract]	'	'	'
Number of operating segments	'	'	3
Segment Reporting Information	'	'	'
Total net revenue	$1,679	$1,680	'
Income from operations	218	217	'
Segment Total [Member]	'	'	'
Segment Reporting Information	'	'	'
Income from operations	296	288	'
Life Sciences and Diagnostics [Member]	'	'	'
Segment Reporting Information	'	'	'
Total net revenue	591	564	'
Income from operations	100	82	'
Chemical Analysis [Member]	'	'	'
Segment Reporting Information	'	'	'
Total net revenue	417	394	'
Income from operations	94	81	'
Electronic Measurement [Member]	'	'	'
Segment Reporting Information	'	'	'
Total net revenue	671	722	'
Income from operations	$102	$125	'

SEGMENT_INFORMATION_Reconcilia

SEGMENT INFORMATION Reconciliation of Reportable Results (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]	'	'
Total reportable segmentsb income from operations	$296	$288
Restructuring	4	0
Asset impairment	0	-1
Transformational initiatives	-3	-3
Amortization of intangibles	-51	-52
Acquisition and integration costs	-7	-10
Pre separation costs	-20	0
Other	-1	-5
Interest income	2	2
Interest expense	-29	-25
Other income (expense), net	0	1
Income before taxes	$191	$195

SEGMENT_INFORMATION_Segment_As

SEGMENT INFORMATION Segment Assets (Details) (USD $)	Jan. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2013
Segment Reporting Information [Line Items]	'	'
Assets	$10,638	$10,686
Life Sciences and Diagnostics [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Assets	4,287	4,291
Chemical Analysis [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Assets	1,757	1,756
Electronic Measurement [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Assets	1,929	1,997
Segment Total [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Assets	$7,973	$8,044